Volume 15 Issue 3
May  2024
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2024  >  15(3): 333-351
Diabetology Committee of Chinese Research Hospital Association, Chinese Diabetes Society, Diabetes Branch of Beijing Medical Association, et al. Expert consensus on the use of hypoglycemic drugs in post transplantation diabetes mellitus (2024 edition)[J]. ORGAN TRANSPLANTATION, 2024, 15(3): 333-351. doi: 10.3969/j.issn.1674-7445.2024111
Citation: Diabetology Committee of Chinese Research Hospital Association, Chinese Diabetes Society, Diabetes Branch of Beijing Medical Association, et al. Expert consensus on the use of hypoglycemic drugs in post transplantation diabetes mellitus (2024 edition)[J]. ORGAN TRANSPLANTATION, 2024, 15(3): 333-351. doi: 10.3969/j.issn.1674-7445.2024111
shu

Expert consensus on the use of hypoglycemic drugs in post transplantation diabetes mellitus (2024 edition)

doi: 10.3969/j.issn.1674-7445.2024111
More Information
  • Corresponding author: Xu Chun, Department of Endocrinology, the Third Medical Center of People′s Liberation Army General Hospital, Beijing 100039, China, Email: xuchh2000-1@163.com; Xiao Xinhua, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Key Laboratory of Endocrinology, National Health Commission, Beijing 100730, China, Email: xiaoxh2014@vip.163.com; Dou Jingtao, Department of Endocrinology, the First Medical Center of People′s Liberation Army General Hospital, People′s Liberation Army Key Laboratory of Endocrinology and Metabolic Diseases, Beijing 100853, China, Email: jingtaodou@163. com; Guo Lixin, Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China, Email: glx1218@163.com
  • Received Date: 2024-04-02
    Available Online: 2024-04-29
  • Publish Date: 2024-05-07
    Abstract
  • In recent years, increasing clinical evidence has been accumulated to support the diagnosis and treatment of post transplantation diabetes mellitus (PTDM), especially the advent of novel hypoglycemic drugs and glucose monitoring technologies, which further promotes the advancement of diagnosis and treatment of PTDM. To elaborate the use of hypoglycemic drugs in PTDM, Diabetology Committee of Chinese Research Hospital Association, Chinese Diabetes Society and Diabetes Branch of Beijing Medical Association jointly organized relevant experts to compile Expert consensus on the use of hypoglycemic drugs in post transplantation diabetes mellitus (2024 Edition), which mainly focuses on the hypoglycemic mechanism, recommended intensity, cautions in clinical application and the interaction with immunosuppressants, aiming to further enhance clinical management level for PTDM patients and improve clinical outcomes. The release of this expert consensus will contribute to standardizing clinical diagnosis and treatment of PTDM.

     

    • FullText(HTML)
  • loading
    • References(80)
  • [1]
    Oxford centre for evidence-based medicine levels of evidence[EB/OL]. [2024-01-10].https://www.docin.com/ p-776102919.html.
    [2]
    MONTORI VM, BASU A, ERWIN PJ, et al. Posttransplantation diabetes: a systematic review of the literature[J]. Diabetes Care, 2002, 25(3): 583-592. DOI: 10.2337/diacare.25.3.583.
    [3]
    CHAMBERS DC, PERCH M, ZUCKERMANN A, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: thirty-eighth adult lung transplantation report—2021; focus on recipient characteristics[J]. J Heart Lung Transplant, 2021, 40(10): 1060-1072. DOI: 10.1016/j.healun.2021.07.021.
    [4]
    NEWMAN JD, SCHLENDORF KH, COX ZL, et al. Post-transplant diabetes mellitus following heart transplantation[J]. J Heart Lung Transplant, 2022, 41(11): 1537-1546. DOI: 10.1016/j.healun.2022.07.011.
    [5]
    LINDER KE, BAKER WL, ROCHON C, et al. Evaluation of posttransplantation diabetes mellitus after liver transplantation: assessment of insulin administration as a risk factor[J]. Ann Pharmacother, 2016, 50(5): 369-375. DOI: 10.1177/1060028015627662.
    [6]
    JENSSEN T, HARTMANN A. Post-transplant diabetes mellitus in patients with solid organ transplants[J]. Nat Rev Endocrinol, 2019, 15(3): 172-188. DOI: 10.1038/s41574-018-0137-7.
    [7]
    AHMED SH, BIDDLE K, AUGUSTINE T, et al. Post-transplantation diabetes mellitus[J]. Diabetes Ther, 2020, 11(4): 779-801. DOI: 10.1007/s13300-020-00790-5.
    [8]
    BEE YM, TAN HC, TAY TL, et al. Incidence and risk factors for development of new-onset diabetes after kidney transplantation[J]. Ann Acad Med Singap, 2011, 40(4): 160-167. DOI: 10.47102/annals-acadmedsg.V40N4 p160.
    [9]
    YEH H, LIN C, LI YR, Et al. Temporal trends of incident diabetes mellitus and subsequent outcomes in patients receiving kidney transplantation: a national cohort study in Taiwan[J]. Diabetol Metab Syndr, 2020, 12: 34. DOI: 10.1186/s13098-020-00541-3.
    [10]
    LIM WH, LOK CE, KIM SJ, et al. Impact of pretransplant and new-onset diabetes after transplantation on the risk of major adverse cardiovascular events in kidney transplant recipients: a population-based cohort study[J]. Transplantation, 2021, 105(11): 2470-2481. DOI: 10.1097/TP.0000000000003639.
    [11]
    SHARIF A, HECKING M, DE VRIES AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014, 14(9): 1992-2000. DOI: 10.1111/ajt.12850.
    [12]
    American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: standards of care in diabetes—2024[J]. Diabetes Care, 2024, 47(Suppl 1): S20-S42. DOI: 10.2337/dc24-S002.
    [13]
    SENIOR PA, ALMEHTHEL M, MILLER A, et al. Diabetes and transplantation[J]. Can J Diabetes, 2018, 42(Suppl 1): S145-S149. DOI: 10.1016/j.jcjd.2017.10.017.
    [14]
    XIA M, YANG H, TONG X, et al. Risk factors for new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis[J]. J Diabetes Investig, 2021, 12(1): 109-122. DOI: 10.1111/jdi.13317.
    [15]
    SUAREZ O, PARDO M, GONZALEZ S, et al. Diabetes mellitus and renal transplantation in adults: is there enough evidence for diagnosis, treatment, and prevention of new-onset diabetes after renal transplantation?[J]. Transplant Proc, 2014, 46(9): 3015-3020. DOI: 10.1016/j.transproceed.2014.07.011.
    [16]
    CHEUNGPASITPORN W, THONGPRAYOON C, VIJAYVARGIYA P, et al. The risk for new-onset diabetes mellitus after kidney transplantation in patients with autosomal dominant polycystic kidney disease: a systematic review and meta-analysis[J]. Can J Diabetes, 2016, 40(6): 521-528. DOI: 10.1016/j.jcjd.2016.03.001.
    [17]
    DAVIDSON J, WILKINSON A, DANTAL J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines[J]. Transplantation, 2003, 75(10 Suppl): SS3-SS24. DOI: 10.1097/01.TP.0000069952.49242.3E.
    [18]
    YATES CJ, FOURLANOS S, COLMAN PG, et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin[J]. Transplantation, 2013, 96(8): 726-731. DOI: 10.1097/TP.0b013e3182a012f3.
    [19]
    YATES CJ, FOURLANOS S, COLMAN PG, et al. Divided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation[J]. Nephrol Dial Transplant, 2014, 29(3): 698-705. DOI: 10.1093/ndt/gft377.
    [20]
    SCHWAIGER E, KRENN S, KURNIKOWSKI A, et al. Early postoperative basal insulin therapy versus standard of care for the prevention of diabetes mellitus after kidney transplantation: a multicenter randomized trial[J]. J Am Soc Nephrol, 2021, 32(8): 2083-2098. DOI: 10.1681/ASN.2021010127.
    [21]
    DOS SANTOS Q, HORNUM M, TERRONES-CAMPOS C, et al. Posttransplantation diabetes mellitus among solid organ recipients in a danish cohort[J]. Transpl Int, 2022, 35: 10352. DOI: 10.3389/ti.2022.10352.
    [22]
    SHARIF A, CHAKKERA H, DE VRIES APJ, et al. International consensus on post-transplantation diabetes mellitus [EB/OL]. [2024-01-10].https://pubmed. ncbi.nlm.nih.gov/38171510/.
    [23]
    INZUCCHI SE, BERGENSTAL RM, BUSE JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)[J]. Diabetes Care, 2012, 35(6): 1364-1379. DOI: 10.2337/dc12-0413.
    [24]
    SHEN T, ZHUANG L, SUN XD, et al. Expert consensus on management of metabolic disease in Chinese liver transplant recipients[J]. World J Gastroenterol, 2020, 26(27): 3851-3864. DOI: 10.3748/wjg.v26.i27.3851.
    [25]
    中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020 年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.

    Branch of Diabetes of Chinese Medical Association. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)[J]. Chin J Diabetes, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.
    [26]
    LU J, MA X, ZHOU J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes[J]. Diabetes Care, 2018, 41(11): 2370-2376. DOI: 10.2337/dc18-1131.
    [27]
    BECK RW, BERGENSTAL RM, RIDDLESWORTH TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials[J]. Diabetes Care, 2019, 42(3): 400-405. DOI: 10.2337/dc18-1444.h.
    [28]
    KRISTENSEN K, ÖGGE LE, SENGPIEL V, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies[J]. Diabetologia, 2019, 62(7): 1143-1153. DOI: 10.1007/s00125-019-4850-0.
    [29]
    LU J, WANG C, SHEN Y, et al. Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 diabetes: a prospective cohort study[J]. Diabetes Care, 2021, 44(2): 549-555. DOI: 10.2337/dc20-1862.
    [30]
    中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(10): 936-948. DOI: 10.3760/cma.j.cn115791-20210810-00436.

    Branch of Diabetes of Chinese Medical Association. Clinical application guideline for blood glucose monitoring in China (2021 edition)[J]. Chin J Diabetes, 2021, 13(10): 936-948. DOI: 10.3760/cma.j.cn115791-20210810-00436.
    [31]
    VEST LS, KORAISHY FM, ZHANG Z, et al. Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: a retrospective analysis of integrated registry and pharmacy claims data[J]. Clin Transplant, 2018, 32(8): e13302. DOI: 10.1111/ctr.13302.
    [32]
    KWON S, KIM YC, KWON H, et al. Metformin use and long-term clinical outcomes in kidney transplant recipients[J]. Am J Kidney Dis, 2023, 82(3): 290-299. DOI: 10.1053/j.ajkd.2023.01.446.
    [33]
    RAM E, LAVEE J, TENENBAUM A, et al. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation[J]. Cardiovasc Diabetol, 2019, 18(1): 118. DOI: 10.1186/s12933-019-0925-y.
    [34]
    BEDANOVA H, HORVATH V, ONDRASEK J, et al. Metformin therapy and risk of cancer in patients after heart transplantation[J]. Bratisl Lek Listy, 2021, 122(5): 305-309. DOI: 10.4149/BLL_2021_051.
    [35]
    PELED Y, LAVEE J, RAICHLIN E, et al. Metformin therapy reduces the risk of malignancy after heart transplantation[J]. J Heart Lung Transplant, 2017, 36(12): 1350-1357. DOI: 10.1016/j.healun.2017.06.009.
    [36]
    CROWLEY MJ, DIAMANTIDIS CJ, MCDUFFIE JR, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review[J]. Ann Intern Med, 2017, 166(3): 191-200. DOI: 10.7326/M16-1901.
    [37]
    WEN YK. Impact of acute kidney injury on metformin-associated lactic acidosis[J]. Int Urol Nephrol, 2009, 41(4): 967-972. DOI: 10.1007/s11255-009-9549-6.
    [38]
    CAI Z, WU X, SONG Z, et al. Metformin potentiates nephrotoxicity by promoting NETosis in response to renal ferroptosis[J]. Cell Discov, 2023, 9(1): 104. DOI: 10.1038/s41421-023-00595-3.
    [39]
    LEE MC, LEE CH, CHANG LY, et al. Association of metformin use with end-stage renal disease in patients with type 2 diabetes mellitus: a nationwide cohort study under the pay-for-performance program[J]. J Clin Pharmacol, 2019, 59(11): 1443-1452. DOI: 10.1002/jcph.1452.
    [40]
    KHARAZMKIA A, AHMADPOOR P, ZIAEI S, et al. Effects of pioglitazone on blood glucose and inflammatory markers of diabetic kidney transplant patients: a randomized controlled trial[J]. Iran J Kidney Dis, 2014, 8(5): 408-416.
    [41]
    ARASHNIA R, ROOHI-GILANI K, KARIMI-SARI H, et al. Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial[J]. J Nephropathol, 2015, 4(2): 48-53. DOI: 10.12860/ jnp.2015.10. DOI: 10.12860/jnp.2015.10.
    [42]
    闫赋琴, 徐春, 程海梅, 等. 瑞格列奈治疗肾移植后糖尿病的疗效和安全性[J]. 武警医学, 2016, 27(5): 449-451. DOI: 10.3969/j.issn.1004-3594.2016.05.006.

    YAN FQ, XU C, CHENG HM, et al. A clinical study on repaglinide therapy of diabetes mellitus after renal transplantation[J]. Med J Chine People's Armed Police Forces, 2016, 27(5): 449-451. DOI: 10.3969/j.issn.1004-3594.2016.05.006.
    [43]
    NIU YJ, SHEN ZY, XU C, et al. Establishment of tacrolimus-induced diabetes in rat model and assessment of clinical treatments for post-transplant diabetes mellitus in liver transplant recipients[J]. Clin Lab, 2013, 59(7/8): 869-874. DOI: 10.7754/clin.lab.2012.120913.
    [44]
    非磺脲类胰岛素促泌剂瑞格列奈临床应用共识[J]. 中国全科医学, 2010, 13(16): 1804.

    Consensus on the clinical application of non sulfonylurea insulin secretagogue regagliptin[J].Chin Gen Pract, 2010,13(16): 1804 .
    [45]
    KAJOSAARI LI, NIEMI M, NEUVONEN M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide[J]. Clin Pharmacol Ther, 2005, 78(4): 388-399. DOI: 10.1016/j.clpt.2005.07.005.
    [46]
    LANE JT, ODEGAARD DE, HAIRE CE, et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation[J]. Transplantation, 2011, 92(10): e56-e57. DOI: 10.1097/TP.0b013e3182347ea4.
    [47]
    BOERNER BP, MILES CD, SHIVASWAMY V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation[J]. Int J Endocrinol, 2014: 617638. DOI: 10.1155/2014/617638.
    [48]
    STRØM HALDEN TA, ÅSBERG A, VIK K, et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation[J]. Nephrol Dial Transplant, 2014, 29(4): 926-933. DOI: 10.1093/ndt/gft536.
    [49]
    SOLIMAN AR, FATHY A, KHASHAB S, et al. Sitagliptin might be a favorable antiobesity drug for new onset diabetes after a renal transplant[J]. Exp Clin Transplant, 2013, 11(6): 494-498. DOI: 10.6002/ect.2013.0018.
    [50]
    HAIDINGER M, WERZOWA J, HECKING M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial[J]. Am J Transplant, 2014, 14(1): 115-123. DOI: 10.1111/ajt.12518.
    [51]
    SANYAL D, GUPTA S, DAS P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting[J]. Indian J Endocrinol Metab, 2013, 17(Suppl 1): S203-S205. DOI: 10.4103/2230-8210.119572.
    [52]
    ATTALLAH N, YASSINE L. Linagliptin in the management of type 2 diabetes mellitus after kidney transplant[J]. Transplant Proc, 2021, 53(7): 2234-2237. DOI: 10.1016/j.transproceed.2021.07.035.
    [53]
    ABDELAZIZ TS, ALI AY, FATTHY M. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in kidney transplant recipients with post-transplant diabetes mellitus (PTDM)-a systematic review and meta-analysis[J]. Curr Diabetes Rev, 2020, 16(6): 580-585. DOI: 10.2174/1573399815666190321144310.
    [54]
    BERGMAN AJ, COTE J, YI B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor[J]. Diabetes Care, 2007, 30(7): 1862-1864. DOI: 10.2337/dc06-2545.
    [55]
    HE YL, SABO R, CAMPESTRINI J, et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase Ⅳ (DPP-4) inhibitor vildagliptin[J]. Eur J Clin Pharmacol, 2007, 63(7): 677-686. DOI: 10.1007/s00228-007-0312-6.
    [56]
    BAE J, LEE MJ, CHOE EY, et al. Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study[J]. Endocrinol Metab (Seoul), 2016, 31(1): 161-167. DOI: 10.3803/EnM.2016.31.1.161.
    [57]
    CHEWCHARAT A, PRASITLUMKUM N, THONGPRAYOON C, et al. Efficacy and safety of SGLT-2 inhibitors for treatment of diabetes mellitus among kidney transplant patients: a systematic review and meta-analysis[J]. Med Sci (Basel), 2020, 8(4): 47. DOI: 10.3390/medsci8040047.
    [58]
    OIKONOMAKI D, DOUNOUSI E, DUNI A, et al. Incretin based therapies and SGLT-2 inhibitors in kidney transplant recipients with diabetes: a systematic review and meta-analysis[J]. Diabetes Res Clin Pract, 2021, 172: 108604. DOI: 10.1016/j.diabres.2020.108604.
    [59]
    HALDEN T, KVITNE KE, MIDTVEDT K, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus[J]. Diabetes Care, 2019, 42(6): 1067-1074. DOI: 10.2337/dc19-0093.
    [60]
    LIM JH, KWON S, JEON Y, et al. The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients[J]. Transplantation, 2022, 106(9): e404-e412. DOI: 10.1097/TP.0000000000004228.
    [61]
    SÁNCHEZ FRUCTUOSO AI, BEDIA RABA A, BANEGAS DERAS E, et al. Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: an observational multicentre study[J]. Clin Kidney J, 2023, 16(6): 1022-1034. DOI: 10.1093/ckj/sfad007.
    [62]
    HISADOME Y, MEI T, NOGUCHI H, et al. Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with pretransplant type 2 diabetes mellitus: a retrospective, single-center, inverse probability of treatment weighting analysis of 85 transplant patients[J]. Transplant Direct, 2021, 7(11): e772. DOI: 10.1097/TXD.0000000000001228.
    [63]
    CEHIC MG, MUIR CA, GREENFIELD JR, et al. Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients[J]. Transplant Direct, 2019, 5(5): e450. DOI: 10.1097/TXD.0000000000000885.
    [64]
    SAMMOUR Y, NASSIF M, MAGWIRE M, et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors in heart transplant patients with type 2 diabetes: initial report from a cardiometabolic center of excellence[J]. J Heart Lung Transplant, 2021, 40(6): 426-429. DOI: 10.1016/j.healun.2021.02.012.
    [65]
    CHA BM, DAVOUDI R, DIVITA MC, et al. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis after orthotopic heart transplant in a prediabetic patient: a case report[J]. Transplant Proc, 2021, 53(8): 2636-2639. DOI: 10.1016/j.transproceed.2021.08.017.
    [66]
    SWEISS H, SELZNICK L, CONTRERAS J, et al. Safety and efficacy of sodium-glucose cotransporter-2 inhibitors in solid organ transplant recipients[J]. Prog Transplant, 2023, 33(3): 261-265. DOI: 10.1177/15269248231189880.
    [67]
    HALDEN TA, EGELAND EJ, ÅSBERG A, et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes[J]. Diabetes Care, 2016, 39(4): 617-624. DOI: 10.2337/dc15-2383.
    [68]
    SINGH P, TAUFEEQ M, PESAVENTO TE, et al. Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: a retrospective study[J]. Diabetes Obes Metab, 2020, 22(5): 879-884. DOI: 10.1111/dom.13964.
    [69]
    KIM HS, LEE J, JUNG CH, et al. Dulaglutide as an effective replacement for prandial insulin in kidney transplant recipients with type 2 diabetes mellitus: a retrospective review[J]. Diabetes Metab J, 2021, 45(6): 948-953. DOI: 10.4093/dmj.2020.0180.
    [70]
    THANGAVELU T, LYDEN E, SHIVASWAMY V. A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation[J]. Diabetes Ther, 2020, 11(4): 987-994. DOI: 10.1007/s13300-020-00786-1.
    [71]
    SINGH P, PESAVENTO TE, WASHBURN K, et al. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients[J]. Diabetes Obes Metab, 2019, 21(4): 1061-1065. DOI: 10.1111/dom.13619.
    [72]
    SWEISS H, HALL R, ZEILMANN D, et al. Single-center evaluation of safety & efficacy of glucagon-like peptide-1 receptor agonists in solid organ transplantation[J]. Prog Transplant, 2022, 32(4): 357-362. DOI: 10.1177/15269248221122867.
    [73]
    KUKLA A, HILL J, MERZKANI M, et al. The use of GLP1R agonists for the treatment of type 2 siabetes in kidney transplant recipients[J]. Transplant Direct, 2020, 6(2): e524. DOI: 10.1097/TXD.0000000000000971.
    [74]
    YUGUEROS GONZÁLEZ A, KANTER J, SANCHO A, et al. Institutional experience with new antidiabetic drugs in kidney transplant[J]. Transplant Proc, 2021, 53(9): 2678-2680. DOI: 10.1016/j.transproceed.2021.08.042.
    [75]
    SATO T, AZUMA Y, OZONE C, et al. Possible advantage of glucagon-like peptide 1 receptor agonists for kidney transplant recipients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2023, 108(10): 2597-2603. DOI: 10.1210/clinem/dgad177.
    [76]
    SOLIMAN AR, SOLIMAN H, AHMED RM. Effect of insulin degludec versus insulin glargine on glycemic variability in patients with renal transplantation with pre-existing type 2 diabetes mellitus; a 1-year, randomized, treat-to-target pilot trial[J]. Iran J Kidney Dis, 2021, 15(5): 385-390.
    [77]
    冉兴无, 母义明, 朱大龙, 等. 成人2 型糖尿病基础胰岛素临床应用中国专家指导建议(2020 版)[J]. 中国糖尿病杂志, 2020, 28(10): 721-728. DOI: 10.3969/j.issn.1006-6187.2020.10.001.

    RAN XW, MU YM, ZHU DL, et al. Chinese expert recommendations on basal insulin treatment in adult type 2 diabetes mellitus[J]. Chin J Diabetes, 2020, 28(10): 721-728. DOI: 10.3969/j.issn.1006-6187.2020.10.001.
    [78]
    中华医学会内分泌学分会. 预混胰岛素临床应用专家共识(2016 年版)[J]. 药品评价, 2016, 13(9): 5-11. DOI: 10.3969/j.issn.1672-2809.2016.09.002.

    Chinese Society of Endocrinology. Chinese experts consensus statement on premixed insulin in the clinical practice[J]. Drug Eval, 2016, 13(9): 5-11. DOI: 10.3969/j.issn.1672-2809.2016.09.002.
    [79]
    朱大龙, 赵维纲, 匡洪宇, 等. 德谷门冬双胰岛素临床应用专家指导意见[J]. 中华糖尿病杂志, 2021, 13(7): 695-701. DOI: 10.3760/cma.j.cn115791-20210506-00247.

    ZHU DL, ZHAO WG, KUANG HY, et al. Expert consensus on clinical application of insulin degludec/insulin aspart[J]. Chin J Diabetes, 2021, 13(7): 695-701. DOI: 10.3760/cma.j.cn115791-20210506-00247.
    [80]
    母义明, 朱大龙, 李焱, 等. 速效胰岛素类似物临床应用专家指导意见[J]. 药品评价, 2016, 13(21): 13-17,53. DOI: 10.3969/j.issn.1672-2809.2016.21.002.

    MU YM, ZHU DL, LI Y, et al. Experts opinion of rapid-acting insulin analogs on clinical applications[J]. Drug Eval, 2016, 13(21): 13-17,53. DOI: 10.3969/j.issn.1672-2809.2016.21.002.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (50) PDF downloads(21) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return